Skip to main content
. 2022 Jan 30;2022:1315299. doi: 10.1155/2022/1315299

Table 3.

A table to show the previous studies performed evaluating the clinical outcomes of DMEK after glaucoma surgery.

Paper Number of patients Previous glaucoma surgery Length of follow-up VA improvement Rate of ECD loss postop Primary graft failure Rebubbling rates Secondary graft failure Postoperative IOP
Alshaker et al., 2021 [160] N = 48 DMEK,
N = 41 DSAEK
62.5% tube,
37.5% trab only,
61.0% tube,
39.0% trab only
30.0 ± 15.5 months,
33.9 ± 22.5 months
Postoperative BCVA was significantly better in DMEK group at 24 months (p = 0.047) 57%,
50%
(p = 0.886)
at 36 months
14.6%,
14.6%
(p = 1.0)
25.0%,
19.5%
(P = 0.615
20.8%,
19.5%
(p = 1.0)
14.6%,
17.1%
(IOP: 25–45 mmHg)
(P = 0.768)
Fili et al., 2021 [161] N = 16 DMEK,
N = 9 DSAEK,
N = 15 PK
68.8% trab, 43.8% tube,
100.0% trab,
22.2% tube,
80.0% trab,
40% tube,
24 months Final BCVA at 24 months
0.34 ± 0.29
0.17 ± 0.18
0.06 ± 0.07
50.7%,
48.9%,
42.7%
at 12 months (P < 0.45)
6.25%,
11.11%,
0
N/A 12.5%,
33.33%,
13.33%
6.25%,
11.11%,
0
Bonnet et al., 2020 [158] N = 11 medically treated GL,
N = 38
surgically treated Gl,
N = 41
no GL
55.3% previous trab, 68.4% previous tube 38.4 ± 11.2 months Achieved BCVA of ≥20/20,
46%,
8%,
49%
(p<0.01)
47.6%,
63.8%,
44.0%
(p<0.05)
0%,
0%,
0%
18.2%,
15.8%,
19.5%
(p = 0.93)
0%,
41.6%,
2.4%
(p<0.05)
54.5%,
26.3%,
34.1%
(IOP >24 mm Hg or >8 increase)
(p = 0.21)
Sorkin et al., 2020 [162] N = 51 surgically treated Gl,
N = 43 controls
49.0% previous tube,
13.7% trab and tube,
37.3% previous trab
37.9 ± 15.2 months,
33.8 ± 13.5 months
Mean BCVA improved from 1.82 ± 0.88 logMAR preop to 1.06 ± 0.87 at 6 months (no comparison to controls) 74%,
52%
at 48 months (P=0.004)
15.7%,
11.6%
P = 0.766
23.5%,
30.2%
P = 0.491
47.1%,
0%
P<0.001
7.8%
(control group not reported)
Boutin et al., 2020 [163] N = 27 44.4% prior tube,
33.3% prior trab,
14.8% trab and tube,
3.7% trab and gold Microshunt,
3.7% prior tube and hydrus
14.6 ± 6.1 months Mean BCVA improved from 1.34 ± 0.65 logMAR preop to 0.50 ± 0.33 at 1 year 50.4% at one year
(P=0.001)
3.7% 18.5% 10.3% 3.7%
Lin et al., 2019 [164] N = 46 DMEK
N = 46 DSEK
48% prior trab, 78% prior tube,
50% prior trab, 74% prior tube
12 months Improved by -0.89 logMAR,
-0.62 logMAR
(p=0.005)
N/A
N/A
2%
2%
(p = 0.65)
22%
9%
(p = 0.14)
0%
17%
(p=0.006)
30% IOP elevation,
36% IOP elevation (increase >8 mmHg)
(p = 0.66)
Birbal et al., 2018 [153] N = 23 65% trabeculectomy,
100% tubes (85% 1 tube, 15% 2 tubes)
19 ± 17 months BCVA improved by  ≥ 2 Snellen lines in 73% 71% 8.7% 21.7% 8.7% 9% (IOP >24 mmHg or >10 mmHg increase)
Aravena et al., 2017 [165] N = 14 medically treated GL,
N = 34
surgically treated Gl,
N = 60
no GL
52.9% tube only,
14.7% trab and tube,
32.3% trab only
9.7 ± 7.3 months Achieved BCVA of ≥20/25,
71.4%,
32.4%,
62.6%
P<0.0001
29.9 ± 12.0%,
44.6 ± 17.8%,
32.7 ± 11.3%,
P=0.001
0,
0,
1.7%
P = 1.0
21.4%,
23.5%,
23.3%
0,
0,
0
50.0%,
14.7%,
23.3%
(p=0.001)

N: number; DMEK: Descemet membrane endothelial keratoplasty; DSAEK: Descemet striping automated endothelial keratoplasty; BCVA: best corrected visual acuity; ECD: endothelial cell density; IOP: intraocular pressure; GL: glaucoma.

HHS Vulnerability Disclosure